Aclaris Therapeutics, Inc.

Historical 13F Holders

Symbol
ACRS
CUSIP
00461U105
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 00461U105 since 12/18/2024, largest first.

Filer % of Class Filed
BML Investment Partners, L.P. 13G/A 9.9% 4/27/2026
Event 4/23/2026
Bonita Biotech (HK) Ltd 13G/A
9.4% 1/9/2026
Event 12/9/2025
RA Capital Management, L.P. 13G/A
9.1% 8/14/2026
Event 6/30/2026
Deep Track Capital, LP 13G
7.0% 3/17/2026
Event 3/9/2026
BlackRock, Inc. 13G/A 6.2% 1/21/2026
Event 12/31/2025
Frazier Life Sciences Public Fund, L.P. 13G
5.4% 9/21/2026
Event 9/14/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Adage Capital Management, L.P. 13G/A
4.9% 11/13/2025
Event 9/30/2025
Rock Springs Capital Management LP 13G/A
4.7% 5/15/2025
Event 3/31/2025
Vivo Opportunity Fund Holdings, L.P. 13G/A
4.3% 5/12/2026
Event 3/31/2026
Millennium Management LLC 13G/A
3.5% 7/24/2025
Event 6/30/2025
Vanguard Group Inc 13G/A 0% 3/26/2026
Event 3/13/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 113 76.5 M $401M
2026 Q2 149 119 M $630M
2026 Q1 137 111 M $414M
2025 Q4 122 83.7 M $252M
2025 Q3 103 85.7 M $163M
2025 Q2 97 91.9 M $130M
2025 Q1 110 92.7 M $144M
2024 Q4 100 87.5 M $217M
2024 Q3 83 50.9 M $58.6M
2024 Q2 99 52.9 M $58.1M
2024 Q1 99 54.4 M $67.8M
2023 Q4 108 58.5 M $61.4M
2023 Q3 145 70.1 M $480M
2023 Q2 135 71.1 M $737M
2023 Q1 153 71.6 M $579M
2022 Q4 131 65.9 M $1.04B
2022 Q3 128 63.6 M $1.00B
2022 Q2 117 63.3 M $883M
2022 Q1 113 59.3 M $1.02B
2021 Q4 134 56.0 M $815M
2021 Q3 127 56.8 M $1.02B
2021 Q2 134 56.0 M $983M
2021 Q1 100 45.4 M $1.30B
2020 Q4 83 31.9 M $207M
2020 Q3 59 25.6 M $65.7M
2020 Q2 63 28.5 M $46.1M
2020 Q1 72 32.1 M $33.4M
2019 Q4 80 30.8 M $58.2M
2019 Q3 82 29.1 M $31.4M
2019 Q2 85 35.7 M $78.1M
2019 Q1 96 37.9 M $227M
2018 Q4 100 39.1 M $289M
2018 Q3 87 29.9 M $435M
2018 Q2 96 32.7 M $652M
2018 Q1 100 30.6 M $536M
2017 Q4 104 28.5 M $703M
2017 Q3 106 28.5 M $737M
2017 Q2 106 25.6 M $694M
2017 Q1 112 23.7 M $707M
2016 Q4 101 21.4 M $579M
2016 Q3 59 15.5 M $397M
2016 Q2 47 15.4 M $284M
2016 Q1 34 14.6 M $277M
2015 Q4 33 10.3 M $277M